97 related articles for article (PubMed ID: 12013358)
1. Serum bactericidal activity of extended-release clarithromycin against macrolide-resistant strains of Streptococcus pneumoniae.
Stein GE; Schooley S
Pharmacotherapy; 2002 May; 22(5):593-6. PubMed ID: 12013358
[TBL] [Abstract][Full Text] [Related]
2. Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones.
Malerczyk C; Kolbert M; Kinzig-Schippers M; Sörgel F; Machka K; Shah PM
J Chemother; 2004 Feb; 16(1):56-61. PubMed ID: 15078000
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae.
Lacy MK; Owens RC; Xu X; Nicolau DP; Quintiliani R; Nightingale CH
Int J Antimicrob Agents; 1998 Nov; 10(4):279-83. PubMed ID: 9916901
[TBL] [Abstract][Full Text] [Related]
4. Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae.
Stein GE; Schooley S
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):181-5. PubMed ID: 11337186
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of clarithromycin against penicillin-susceptible and penicillin-resistant strains of Streptococcus pneumoniae in a pharmacodynamic simulation model.
Fuentes F; Sevillano D; Balcabao IP; Gómez-Lus ML; Prieto J
J Chemother; 2000 Dec; 12(6):495-8. PubMed ID: 11154032
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito S; Noviello S; Ianniello F
J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
Kays MB; Denys GA
Clin Ther; 2001 Mar; 23(3):413-24. PubMed ID: 11318076
[TBL] [Abstract][Full Text] [Related]
8. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae.
Martin SJ; Garvin CG; McBurney CR; Sahloff EG
J Antimicrob Chemother; 2001 May; 47(5):581-7. PubMed ID: 11328768
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations.
Noreddin AM; Roberts D; Nichol K; Wierzbowski A; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2002 Dec; 46(12):4029-34. PubMed ID: 12435719
[TBL] [Abstract][Full Text] [Related]
10. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
[TBL] [Abstract][Full Text] [Related]
11. In vitro comparative dynamics of modified-release clarithromycin and of azithromycin.
Scaglione F; Demartini G; Dugnani S; Fraschini F
Chemotherapy; 2000; 46(5):342-52. PubMed ID: 10965100
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
13. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance.
Craig WA
Am J Med; 2004 Aug; 117 Suppl 3A():16S-22S. PubMed ID: 15360093
[TBL] [Abstract][Full Text] [Related]
14. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK
Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
[TBL] [Abstract][Full Text] [Related]
15. Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study.
Schentag JJ; Klugman KP; Yu VL; Adelman MH; Wilton GJ; Chiou CC; Patel M; Lavin B; Paladino JA
Int J Antimicrob Agents; 2007 Sep; 30(3):264-9. PubMed ID: 17587549
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
Noreddin AM; El-Khatib WF; Aolie J; Salem AH; Zhanel GG
Int J Infect Dis; 2009 Jul; 13(4):483-7. PubMed ID: 19046911
[TBL] [Abstract][Full Text] [Related]
17. Penicillin-resistant and -intermediate Streptococcus pneumoniae in Saudi Arabia.
Shibl AM; Al Rasheed AM; Elbashier AM; Osoba AO
J Chemother; 2000 Apr; 12(2):134-7. PubMed ID: 10789552
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of antimicrobial and bactericidal activities and postantibiotic effects of macrolides antibiotics against clinical isolates, and examination of shape alteration by scanning electron microscope].
Yano H; Kobayashi T; Okitsu N; Aoki A; Toriya M; Nakada Y; Sagai H; Iyobe S; Inoue M
Jpn J Antibiot; 2007 Feb; 60(1):31-46. PubMed ID: 17436861
[TBL] [Abstract][Full Text] [Related]
20. Clarithromycin mediated the expression of polymorphonuclear granulocyte response against streptococcus pneumoniae strains with different patterns of susceptibility and resistance to penicillin and clarithromycin.
Cuffini AM; Tullio V; Mandras N; Roana J; Scalas D; Banche G; Carlone NA
Int J Tissue React; 2002; 24(1):37-44. PubMed ID: 12013153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
